Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,969 | $1,214 | $150,789 | $536,950 |
| - Cash | $4,652 | $2,861 | $2,016 | $2,884 |
| + Debt | $0 | $41 | $44 | $229 |
| Enterprise Value | -$1,683 | -$1,606 | $148,817 | $534,295 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$83 | -$31 | -$35 | -$42 |
| % Margin | – | – | – | – |
| EBITDA | -$7,419 | -$6,870 | -$17,616 | -$32,839 |
| % Margin | – | – | – | – |
| Net Income | -$7,517 | -$6,912 | -$18,571 | -$31,948 |
| % Margin | – | – | – | – |
| EPS Diluted | -8.08 | -29.95 | -11.08 | -19.48 |
| % Growth | 73% | -170.3% | 43.1% | – |
| Operating Cash Flow | -$5,880 | -$6,137 | -$18,501 | -$32,892 |
| Capital Expenditures | $0 | $0 | -$4 | -$11 |
| Free Cash Flow | -$5,880 | -$6,137 | -$18,505 | -$32,903 |